CONMED Corp
About CONMED Corp
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.4B
- Net income
- $47.1M
- Total assets
- $2.3B
- Market cap
- $1.1B
- Gross margin
- 54.6%
- Operating margin
- 7.5%
- Net margin
- 3.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4B
- Cost of revenue
- $624.2M
- Gross profit
- $750.5M
- Operating expenses
- $647.9M
- Operating income
- $102.6M
- Income tax
- $24.1M
- Net income
- $47.1M
- EPS (basic)
- $1.52
- EPS (diluted)
- $1.51
Balance sheet
- Total assets
- $2.3B
- Current assets
- $672.9M
- Total liabilities
- $1.3B
- Current liabilities
- $315.0M
- Shareholders’ equity
- $1.0B
Cash flow
- Operating cash flow
- $170.7M
- Investing cash flow
- -$21.0M
- Financing cash flow
- -$135.8M
- Net cash flow
- $16.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- P/E ratio
- 22.8
- EPS (diluted)
- $1.51
- Dividend yield
- 2.32%
- Shares outstanding
- 30.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 1987
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $47.1M in FY2025.
- Revenue grew 36% from FY2021 to FY2025.
- Gross margin of 54.6%, net margin 3.4%.
- Trading 43% below its 52-week high.
- Pays a dividend yielding about 2.32% annually.
- Valued at a price-to-earnings (P/E) ratio of 22.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review CONMED Corp.
Write a review
News about CONMED Corp
News & sentiment via Polygon.io